Screener
BridgeBio Pharma BBIO CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (52,666) | — |
| Maturities of marketable securities | 10,000 | — |
| Payment for an intangible asset | — | (1,595) |
| Purchases of property and equipment | (69) | — |
| Net cash used in investing activities | (42,735) | (1,595) |
| Financing activities: | ||
| Proceeds from issuance of 2033 Notes | 632,500 | — |
| Issuance costs and discounts associated with 2033 Notes | (12,796) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's capex?
- BridgeBio Pharma (BBIO) reported capex of $69K in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's capex?
- Over 4 years (2021 to 2025), BridgeBio Pharma's capex has grown at a -46.4% compound annual growth rate (CAGR), from $13.25M to $1.1M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about BridgeBio Pharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude